 |
6 Diseases |  |
125 Trials |
|
125 Trials |  |
2571 News |  |
| «12...2223242526272829303132...3334» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Colon cancer in the elderly: A comprehensive assessment of treatment and its outcomes () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_232;
As first-line for metastatic disease, 57 patients were treated: 13 with FOLFIRI/bevacizumab, 11 capecitabine, 7 with either FOLFIRI, FOLFOX/bevacizumab or FOLFIRI/cetuximab and the rest with other regimens...9 patients were fit to start a 3rd line, with 3 submitted to TAS 102 as well as 1 patient that also received the same drug as a 4th therapeutic line...Legal entity responsible for the study The authors. Funding Has not received any funding.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Effectiveness and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer in clinical practice in Poland () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_205;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer, irinotecan / Generic mfg.
[VIRTUAL] Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_181;
Legal entity responsible for the study The authors. Funding Medical University of Varna.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
[VIRTUAL] Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_175;
Legal entity responsible for the study The authors. Funding This study was not funded and was entirely supported by Università Politecnica delle Marche - AOU Ospedali Riuniti di Ancona.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
[VIRTUAL] Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY) () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_144;
Funding REMETY was supported by a grant from Bayer Vital. Sponsor: AIO-Studien-gGmbH, Berlin, Germany.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
[VIRTUAL] Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_143;
Funding This investigator-initiated study was partly funded by Servier and the funding was used to collect clinical data according to the protocol. The good clinical practice units in Denmark monitors the study.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, TAS / 102
Retrospective data, Journal, Monotherapy: Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. (Pubmed Central) - May 9, 2020
The good clinical practice units in Denmark monitors the study. In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, irinotecan / Generic mfg.
Journal, HEOR: Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. (Pubmed Central) - May 7, 2020
In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities. The results indicate that FTD/TPI may represent a cost-effective treatment option compared with other alternative therapies as a third-line treatment of metastatic colorectal cancer in Greece.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Journal: Sarcopenia in Metastatic Colorectal Carcinoma. (Pubmed Central) - May 2, 2020
10. 2019.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, TAS / 102
Clinical, Monotherapy: we showed TAS-102 plus bevacizumab prolonged median progression-free survival (2·6 months in patients receiving TAS-102 monotherapy vs 4·6 months in patients receiving TAS-102 plus bevacizumab) with limited toxicity in patients with chemorefractory metastatic colorectal cancer. (Twitter) - May 2, 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical, Clinical guideline, Review, Journal: Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). (Pubmed Central) - May 1, 2020
These recommendations are permanently being reviewed and updated. Each individual case must be discussed within a multidisciplinary team (MDT).
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical, Journal: Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102. (Pubmed Central) - Apr 30, 2020
Each individual case must be discussed within a multidisciplinary team (MDT). Although patients who received regorafenib had more SMM loss than those who received TAS-102, there was no difference in OS between drugs.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly
[VIRTUAL] Clinical impact of oral intake on second-line treatment of advanced gastric cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4034;
For appropriate use of oral drugs, CT should be changed in SUF pts with factors associated with EXA. Research Funding: None
- irinotecan / Generic mfg., capecitabine / Generic mfg.
[VIRTUAL] Irinotecan with or without capecitabine as a beyond 2nd line regime for esophago-gastric adenocarcinomas. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4019;
Irinotecan in combination with capecitabine is efficacious as a beyond 2nd line regime in metastatic EG with an acceptable toxicity profile with a limited role in patients with resistant disease to first line platinum-based chemotherapies with fluoropyramidines. Research Funding: None
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, fluorouracil / Generic mfg., TAS / 102
[VIRTUAL] Meta-analysis and systematic review of the cardiotoxicity of TAS-102. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3879;
Since fluoropyrimidines remain the backbone of treatment for gastrointestinal malignancies, TAS-102 can offer an alternative to patients who developed cardiotoxicities from other agents. Prospective studies with consideration of cardiac risk factors are required.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Journal: Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. (Pubmed Central) - Apr 28, 2020
Prospective studies with consideration of cardiac risk factors are required. No abstract available
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Enrollment open, Trial initiation date: PULSE: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Apr 27, 2020
P2, N=120, Recruiting, Sponsor: Academic and Community Cancer Research United
No abstract available Active, not recruiting --> Recruiting | Initiation date: Nov 2019 --> Apr 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
.@michael_overman on choosing between regorafenib and TAS-102 in CRC #crcsm https://t.co/9lExWX0BWC (Twitter) - Apr 27, 2020
- || Avastin (bevacizumab) / Roche
Clinical, Journal: A Case Report of a Patient Over 90 Years of Age with Liver Metastasis after Sigmoid Colectomy Controlled by a Combination Oral UFT/LV Chemotherapy Regimen (Pubmed Central) - Apr 23, 2020
She died of a sigmoid cancer 32 months after UFT/LV initiation. Careful adaptation of chemotherapy can be used to control a patient's condition during certain periods, even in patients with super-advanced age.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Yeah, I would not put this in the same category as Rego or lonsurf! (Twitter) - Apr 22, 2020
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Clinical, P1 data, PK/PD data, Journal: Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study. (Pubmed Central) - Apr 21, 2020
P1
FTD/TPI had an acceptable safety and efficacy profile and PK characteristics were comparable between Chinese, Japanese, and US patients, suggesting that this treatment may be suitable for Chinese patients with refractory mCRC. This trial was registered at clinicaltrials.gov as NCT02261532.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Maybe they don’t ever prescribe TAS-102 or regorafenib either. This one was a no-brainer. 👍🏼 (Twitter) - Apr 20, 2020
- | Journal, Benefit-risk assessment: Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. (Pubmed Central) - Apr 16, 2020
F-RAM as third-line and later-line treatment for mCRC has a poor risk benefit. TAS-102 should be given priority over F-RAM.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm
Clinical, PK/PD data, Journal: Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment (PI: Dr Saif). (Pubmed Central) - Apr 14, 2020
FTD/TPI is not recommended for use in patients with moderate hepatic impairment because of findings of grade 3 or 4 increased blood bilirubin. Therefore, FTD/TPI is not recommended for patients with moderate or severe hepatic impairment.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical: .@michael_overman discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer @MDAndersonNews #crcsm https://t.co/9lExWX0BWC (Twitter) - Apr 13, 2020
- |||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial primary completion date, Metastases: PRECONNECT: A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). (clinicaltrials.gov) - Apr 12, 2020
P3, N=907, Active, not recruiting, Sponsor: Institut de Recherches Internationales Servier
Therefore, FTD/TPI is not recommended for patients with moderate or severe hepatic impairment. Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jan 2020 --> Jun 2020
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Enrollment closed: PULSE: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Apr 12, 2020
P2, N=120, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jan 2020 --> Jun 2020 Not yet recruiting --> Active, not recruiting
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
Journal: Trifluridine/tipiracil in metastatic gastric cancer. (Pubmed Central) - Apr 10, 2020
Not yet recruiting --> Active, not recruiting No abstract available
- | paclitaxel / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS, irinotecan / Generic mfg.
Retrospective data, Journal: What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. (Pubmed Central) - Apr 10, 2020
The benefit of using non-cross resistant second-line regimens as third-line chemotherapy was small with moderate toxicity. Newer agents such as nivolumab or TAS-102 or clinical trial may be preferred.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial initiation date: LONGBOARD: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (clinicaltrials.gov) - Apr 9, 2020
P2, N=250, Not yet recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Newer agents such as nivolumab or TAS-102 or clinical trial may be preferred. Initiation date: Feb 2020 --> May 2020
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Phase I Prospective Trial of TAS-102 (trifluride and tipiracil) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases (Room 606) - Apr 8, 2020 - Abstract #SIR2020SIR_2;
Severity and incidence of AEs was within the expected range of TAS-102 and Y90 radioembolization monotherapy. A dose-expansion phase with planned enrollment of 12 patients is ongoing.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
Clinical, Journal: Sequencing beyond the second-line setting in metastatic colorectal cancer. (Pubmed Central) - Apr 4, 2020
When sequencing these agents, physicians should consider patient characteristics, including comorbidities, prior adverse reactions to treatments, and overall performance status. Ongoing studies are further defining the role of regorafenib and trifluridine/tipiracil in the treatment of mCRC.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Journal: Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. (Pubmed Central) - Apr 4, 2020
The frequency of sarcopenia increases during the course of mCRC and negatively affects survival. In contrast to TAS-102, regorafenib is associated with increased skeletal muscle loss during mCRC treatment and should therefore be used with caution in mCRC patients with preexisting sarcopenia or a history of recent weight loss.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical: 4️⃣Regorafenib or TAS-102 or anti-HER2⛔️ are valid options. Important to also realize that anti-HER2 trials are ongoing with other drugs and agents. Important to accrue to these #clinicaltrials. @SWOG @MayoClinic ACCRU. #TargetedChat (Twitter) - Mar 30, 2020
- ||||| Clinical: #TargetedChat In case #3, the majority in our poll voted to treat with pertuzumab plus trastuzumab as the next line of therapy, although TAS-102 as well as lepatinib plus trastuzumab were also of high interest. @pashtoonkasi #crcsm #colorectalcancerawarenessmonth (Twitter) - Mar 30, 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Yes, rego would be fine but TAS-102 is fine too. I just use one week on/one week off. Neutropenia is less of an issue. (Twitter) - Mar 30, 2020
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical: A guideline in this regard ( switch to/start Regorafenib instead of TAS-102 ) for #CRC patients that have progressed on multiple lines, during this #covid19--would that be a possibility? @agrothey @guptaarjun90 @NiuSanford @CathyEngMD (Twitter) - Mar 29, 2020
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical: Now with the #Covid19 situation, it seems that patients who were previously scheduled to start Lonsurf (TAS-102) are not getting it. Could Regorafenib be used instead, esp if it doesn't affect blood counts as much & is comparable to TAS-102 and dosing could begin from 40 or 80? (Twitter) - Mar 29, 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
WATCH: Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC #crcsm @michael_overman @MDAndersonNews https://t.co/YsUs9I77dq (Twitter) - Mar 29, 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
.@michael_overman on choosing between regorafenib and TAS-102 in CRC @MDAndersonNews #crcsm https://t.co/9lExWX0BWC (Twitter) - Mar 28, 2020
- ||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Clinical: Consented and sent prior auths on nearly all my patients for cape or lonsurf today just in case can't do infusions in near future. (Twitter) - Mar 23, 2020
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
Clinical, Journal: Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. (Pubmed Central) - Mar 22, 2020
In contrast to TAS-102, regorafenib is associated with increased skeletal muscle loss during mCRC treatment and should therefore be used with caution in mCRC patients with preexisting sarcopenia or a history of recent weight loss. Results suggest reconsidering TAS-102 in patients with ECOG > 0, something that should be investigated in prospective randomized clinical trials.
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Trial initiation date: MOCHA: Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (clinicaltrials.gov) - Mar 19, 2020
P2, N=47, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
Results suggest reconsidering TAS-102 in patients with ECOG > 0, something that should be investigated in prospective randomized clinical trials. Initiation date: Sep 2019 --> Dec 2019
- | Lonsurf (trifluridine/tipiracil) / Otsuka
Enrollment closed, Enrollment change, Trial primary completion date, Surgery, Metastases: TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 18, 2020
P1, N=7, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Sep 2019 --> Dec 2019 Recruiting --> Active, not recruiting | N=24 --> 7 | Trial primary completion date: Mar 2021 --> Mar 2020
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal: Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. (Pubmed Central) - Mar 13, 2020
We developed and validated a reflective MCDA framework for the assessment and positioning of oncologic therapies in Spain. Additional work is needed to create a manual for practical decision making in the clinical setting.
- || Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, TAS / 102
TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC #crcsm https://t.co/Na2jaemJPj (Twitter) - Mar 12, 2020
- Avastin (bevacizumab) / Roche
[VIRTUAL] TREATMENT PATTERNS AND OUTCOMES OF SYSTEMIC THERAPY FOR MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_683;
Patients with MSS mCRC predominately received bevacizumab plus chemotherapy in 1L and 2L, with a high proportion continuing bevacizumab through progression. There was no predominant regimen in 3L and median DOT was less than 3.0 months, which highlights the unmet need for more effective treatment options in 3L.
- [VIRTUAL] A SYSTEMATIC REVIEW AND EXPLORATORY NETWORK META-ANALYSIS OF THIRD-LINE TREATMENTS FOR METASTATIC COLORECTAL CANCER () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_644;
CONCLUSIONS Regorafenib, TAS-102 and SIRT using Y-90 resin microspheres are more effective than BSC in third-line mCRC, however comparisons between active treatments are uncertain because of heterogeneity between the studies. SIRT can be considered an option in this setting and its favorable AE profile is relevant in the therapeutic decision-making process.
- |||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
Clinical: Stivarga + Lonsurf=?? for mCRC.. Anyone heard of results beyond the 12 patients study? @agrothey @pashtoonkasi (Twitter) - Mar 4, 2020
- | Lonsurf (trifluridine/tipiracil) / Otsuka
New P2 trial, Combination therapy, Metastases: TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer (clinicaltrials.gov) - Mar 4, 2020
P2, N=50, Recruiting, Sponsor: Rutgers, The State University of New Jersey